Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
ATRC - AtriCure, Inc.
Market Cap 2.69B P/E - EPS this Y -18.20% Ern Qtrly Grth -
Income -37.23M Forward P/E -65.40 EPS next Y 21.80% 50D Avg Chg 13.00%
Sales 414.6M PEG -1.51 EPS past 5Y - 200D Avg Chg 28.00%
Dividend N/A Price/Book 5.83 EPS next 5Y 20.00% 52W High Chg -5.00%
Recommedations 1.70 Quick Ratio 2.63 Shares Outstanding 48.38M 52W Low Chg 75.00%
Insider Own 3.22% ROA -3.86% Shares Float 46.72M Beta 1.44
Inst Own 103.97% ROE -8.17% Shares Shorted/Prior 3.63M/3.30M Price 56.90
Gross Margin 75.26% Profit Margin -8.98% Avg. Volume 291,016 Target Price 46.13
Oper. Margin -10.03% Earnings Date Jul 30 Volume 376,693 Change 1.16%
Healthcare | Medical Instruments & Supplies | United States
About AtriCure, Inc.

AtriCure, Inc. develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation. It also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Systems, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation; cryoSPHERE probe, which provides temporary pain relief by applying cryothermic energy to targeted intercoastal peripheral nerves in the ribcage; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure. In addition, the company sells Lumitip dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; Subtle Cannula's to support access for EPi-Sense catheters; and various reusable cardiac surgery instruments. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.

AtriCure, Inc. News
07/24/24 AtriCure (ATRC) Gains China Approval for AtriClip LAA System
07/23/24 AtriCure Receives Regulatory Approval to Sell AtriClip® Devices in China
07/09/24 AtriCure to Announce Second Quarter 2024 Financial Results
07/08/24 AtriCure And Two Other Undervalued Small Caps With Insider Actions In The United States
07/03/24 AtriCure Leads Three Undervalued Small Caps With Insider Actions In United States
06/28/24 Have 20 Bucks? 7 Low-Priced Stocks That Could Double by 2025
08:04 AM Exploring Three Undervalued Small Caps With Insider Action In The Region
06:06 AM Exploring Undervalued Small Caps With Insider Buying In The United States June 2024
06/25/24 AtriCure Leads Three Undervalued Small Caps With Insider Actions In The United States
06/24/24 Exploring Undervalued Small Caps With Insider Actions In The United States June 2024
06/21/24 AtriCure (ATRC) Stock Slipped on Competition Threat
06/20/24 June 2024 Insight On Undervalued Small Caps With Insider Transactions
06/14/24 Is AtriCure, Inc. (NASDAQ:ATRC) Trading At A 48% Discount?
05/31/24 Insider Buying: Chief Technical Officer Salvatore Privitera Acquires Shares of AtriCure Inc (ATRC)
05/15/24 AtriCure to Participate in the 2024 Leerink Partners Healthcare Crossroads Conference
05/04/24 AtriCure, Inc. (NASDAQ:ATRC) Just Reported, And Analysts Assigned A US$47.33 Price Target
05/03/24 The past three years for AtriCure (NASDAQ:ATRC) investors has not been profitable
05/03/24 AtriCure First Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
05/02/24 AtriCure, Inc. (NASDAQ:ATRC) Q1 2024 Earnings Call Transcript
05/02/24 AtriCure Inc (ATRC) Q1 2024 Earnings Call Transcript Highlights: Strong Revenue Growth and ...
ATRC Chatroom

User Image Theflash88 Posted - 1 day ago

$ATRC May not happen.. did you see EW today?

User Image Stock_Titan Posted - 3 days ago

$ATRC AtriCure Receives Regulatory Approval to Sell AtriClip® Devices in China https://www.stocktitan.net/news/ATRC/atri-cure-receives-regulatory-approval-to-sell-atri-clip-r-devices-lm1dvf9t1967.html

User Image GoodOlJR Posted - 2 weeks ago

$ATRC opened a small (500 shares) position today @ $22.55. Quick swing trade ride to $25.

User Image Dingusbro Posted - 2 weeks ago

$ATRC when buy out?

User Image QuiverQuant Posted - 2 weeks ago

CONGRESSIONAL TRADING: Representative Josh Gottheimer disclosed a sale of $1,001 - $15,000 of $ATRC on 2024-07-09.

User Image Stock_Titan Posted - 2 weeks ago

$ATRC AtriCure to Announce Second Quarter 2024 Financial Results https://www.stocktitan.net/news/ATRC/atri-cure-to-announce-second-quarter-2024-financial-w45ot9yoa5kd.html

User Image Jamesiam Posted - 2 weeks ago

$ATRC no insider buying

User Image DonCorleone77 Posted - 2 weeks ago

$PLSE $ATRC AtriCure competitor clamp unlikely to launch until 2026 or later, says Needham Needham notes that Pulse Biosciences (PLSE) announced that it received FDA Breakthrough Device Designation for its surgical ablation clamp using pulsed field ablation, or PFA, and plans to pursue a premarket approval for the clamp, which will require a clinical study. This is a change from its prior plans to market the clamp with a 510(k) clearance, says the analyst, who thinks it is unlikely to receive FDA approval until late 2026 or later and believes that this is positive for AtriCure (ATRC). The later-than-anticipated potential launch eliminates a potential near-term competitive threat to AtriCure's U.S. Open-Heart Ablation business and provides the company with time to pursue its own PFA clamp, added the analyst, who maintains a Buy rating and $40 price target on AtriCure shares.

User Image Theflash88 Posted - 3 weeks ago

$ATRC Doesn’t matter. Getting bought out.

User Image DonCorleone77 Posted - 06/30/24

$ATRC AtriCure price target lowered to $35 from $58 at UBS UBS lowered the firm's price target on AtriCure to $35 from $58 and keeps a Buy rating on the shares. The firm said on Friday that shares are down about 35% year-to-date and over 60% off 52-week highs on fears of a dramatic growth slowdown/decline in its AtriClip business, which comprised 40% of sales in 2023 and just over 3 points of sales CAGR over the 2018-2023 timeframe. But UBS sees these fears as dramatically overdone.

User Image StockInvest_us Posted - 4 weeks ago

Signal alert: $ATRC - PivotPoint bottom https://stockinvest.us/l/NO4PQj6uNL

User Image wajtrading Posted - 4 weeks ago

$ATRC looking good.

User Image MavisMVIS Posted - 1 month ago

$ATRC If ZimmerBiomet buys this company I will not be surprised! They would be a perfect addition to their portfolio! I hope it happens. If ZimmerBiomet doesn’t buy them KLS or Johnson and Johnson should! We will see! They are a good company with quality people working and managing the joint!

User Image _StockTrader Posted - 1 month ago

Real-Time Stock Data $ATRC Price: N/A Volume: 3497980 Market Cap: 1025704768 PE Ratio: -34.754097 Powered by: AITX

User Image OpenOutcrier Posted - 1 month ago

RECAP 6/18 Chatter: $AMD - Data Breach $TFPM + Betaville chatter $BALL - Guidance $ATRC + $EW Live Breaking trading news www.openoutcrier.com

User Image Jamesiam Posted - 1 month ago

$ATRC their technology is obsolete

User Image VrtcIl Posted - 1 month ago

Trail your stops on $ATRC to secure profits. Consider strategic placement below prior pivot lows on the technical chart to secure gains and manage potential downside risks effectively. Price: 23.04 Float: 46.0M Short Float: 7.5 % 💰 Dollar Volume: 180.4K ℹ️ USA | Medical Instruments & Supplies

User Image Stonkey Posted - 1 month ago

$ATRC I sold, so now it goes up.

User Image Aigner_Andreas Posted - 2 months ago

TD SELL $ATRC at 22.45, Supp 20.69 Resis 23.14 R12 HiLo 5% T1Y 64 buy 1.7 DIV N/A #AtriCure I #stocks #trading #finance #market

User Image insiderbuyingselling Posted - 2 months ago

$ATRC new insider selling: 1500 shares. http://insiderbuyingselling.com/?t=ATRC

User Image IN0V8 Posted - 2 months ago

$ATRC BTIG cuts target price to $58 from $65 Canaccord Genuity cuts target price to $49 from $57 JP Morgan cuts target price to $34 from $42 Needham cuts target price to $40 from $46 Stifel cuts target price to $30 from $42

User Image Stocksrunner Posted - 2 months ago

📉 Top Losers $FSLY Tumbling on a weak forecast, optimism fades. $FRSH plunges over 25% as CEO departure shakes confidence. $ATRC misses estimates, with revenue up but EPS down. $RELY struggles as earnings call fails to impress. $WEAV feels the sting of disappointing Q1 results. It's a rough day for these stocks, with gloom dominating the market sentiment. 😔 https://stocksrunner.com/trending

User Image epsguid Posted - 2 months ago

$ATRC reported a loss of $0.25, consensus was ($0.21) via @eWhispers #epsmiss http://eps.sh/d/atrc

User Image Estimize Posted - 2 months ago

$ATRC misses the Estimize EPS Consensus by 3c and beats the Estimize Revenue Consensus by $1.44M. Reports FQ1 earnings of -25c EPS and ... http://www.estimize.com/atrc/fq1-2024?utm_content=beat_or_miss&utm_medium=tweet&utm_source=stocktwits

User Image Stock_Titan Posted - 2 months ago

$ATRC AtriCure Reports First Quarter 2024 Financial Results https://www.stocktitan.net/news/ATRC/atri-cure-reports-first-quarter-2024-financial-cap635m3hrot.html

User Image Estimize Posted - 2 months ago

$ATRC reports after the close, Estimize Consensus +0.01 EPS and +0.55M Revs compared to WS http://www.estimize.com/atrc/fq1-2024?utm_content=prerelease&utm_medium=tweet&utm_source=stocktwits

User Image Stock_Titan Posted - 04/30/24

$ATRC AtriCure to Participate in the 2024 Bank of America Securities Healthcare Conference https://www.stocktitan.net/news/ATRC/atri-cure-to-participate-in-the-2024-bank-of-america-securities-kumzsa1y092w.html

User Image briefingcom Posted - 3 months ago

$ATRC (+3.8%) upgraded to Outperform from Perform at Oppenheimer; tgt $32 https://www.briefing.com/calendars/updown?Filter=Upgrades

User Image Stock_Titan Posted - 3 months ago

$ATRC AtriCure Announces Launch of the cryoSPHERE®+ Probe for Post-Operative Pain Management https://www.stocktitan.net/news/ATRC/atri-cure-announces-launch-of-the-cryo-sphere-r-probe-for-post-di71xvdp03oi.html

User Image Stock_Titan Posted - 3 months ago

$ATRC AtriCure to Announce First Quarter 2024 Financial Results https://www.stocktitan.net/news/ATRC/atri-cure-to-announce-first-quarter-2024-financial-d7fuh6h7jh10.html

Analyst Ratings
Needham Buy Jul 8, 24
Canaccord Genuity Buy May 2, 24
JP Morgan Overweight May 2, 24
Needham Buy May 2, 24
Oppenheimer Outperform Apr 23, 24
Needham Buy Apr 10, 24
UBS Buy Feb 16, 24
Stifel Buy Feb 16, 24
Needham Buy Feb 16, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Dahlquist Karl S. Chief Legal Officer Chief Legal Officer Nov 01 Sell 34.43 1,248 42,969 30,789 11/03/23
Dahlquist Karl S. Chief Legal Officer Chief Legal Officer Jul 26 Sell 57.09 3,417 195,077 32,037 07/28/23
Prange Karen Director Director Jun 08 Sell 47.89 713 34,146 16,140 06/12/23
Dahlquist Karl S. Chief Legal Officer Chief Legal Officer Jun 06 Sell 47.03 1,422 66,877 34,897 06/07/23
Yuen Maggie Director Director May 26 Sell 47.04 4,313 202,884 4,682 05/30/23
Collar Mark A Director Director Mar 13 Option 9.30 10,000 93,000 100,871 03/15/23
WHITE ROBERT S. Director Director Aug 31 Option 8.48 15,000 127,200 55,799 09/02/22
Austin Tonya Chief Human Resource.. Chief Human Resources Officer May 13 Sell 42.69 3,203 136,736 17,621 05/17/22
Austin Tonya Chief Human Resource.. Chief Human Resources Officer Apr 08 Sell 61.59 282 17,368 20,824 04/12/22
Collar Mark A Director Director Mar 16 Option 8.40 10,000 84,000 87,307 03/18/22
WHITE ROBERT S. Director Director Mar 03 Option 8.48 15,000 127,200 37,235 03/07/22
Austin Tonya Chief Human Resource.. Chief Human Resources Officer Mar 04 Sell 67.66 1,409 95,333 21,106 03/07/22
Austin Tonya Chief Human Resource.. Chief Human Resources Officer Mar 02 Sell 69.86 4,885 341,266 22,515 03/04/22
Austin Tonya Chief Human Resource.. Chief Human Resources Officer Feb 11 Sell 67.97 2,490 169,245 20,340 02/15/22
Austin Tonya Chief Human Resource.. Chief Human Resources Officer Jan 14 Sell 66.11 2,719 179,753 22,830 01/18/22
WEHRWEIN SVEN Director Director May 05 Option 19.95 5,000 99,750 17,686 05/05/21
CARREL MICHAEL H President, CEO, & Di.. President, CEO, & Director Feb 04 Option 21.04 25,000 526,000 529,795 02/04/21
CARREL MICHAEL H President, CEO, & Di.. President, CEO, & Director Feb 04 Sell 60 25,000 1,500,000 504,795 02/04/21
CARREL MICHAEL H President, CEO, & Di.. President, CEO, & Director Jan 13 Option 21.04 25,000 526,000 529,795 01/13/21
CARREL MICHAEL H President, CEO, & Di.. President, CEO, & Director Jan 13 Sell 59 25,000 1,475,000 504,795 01/13/21
CARREL MICHAEL H President, CEO, & Di.. President, CEO, & Director Dec 28 Option 21.04 25,000 526,000 529,457 12/28/20
CARREL MICHAEL H President, CEO, & Di.. President, CEO, & Director Dec 28 Sell 58 25,000 1,450,000 504,504 12/28/20
CARREL MICHAEL H President, CEO, & Di.. President, CEO, & Director Dec 23 Option 21.04 74,751 1,572,761 529,504 12/23/20
CARREL MICHAEL H President, CEO, & Di.. President, CEO, & Director Dec 23 Sell 56 74,751 4,186,056 504,504 12/23/20
CARREL MICHAEL H President, CEO, & Di.. President, CEO, & Director Dec 21 Option 13.48 125,249 1,688,357 554,753 12/21/20
CARREL MICHAEL H President, CEO, & Di.. President, CEO, & Director Dec 21 Sell 51.63 125,249 6,466,606 504,504 12/21/20